alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.
Company profile
Ticker
DRTS, DRTSW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
DRTS stock data
Latest filings (excl ownership)
6-K
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
25 Mar 24
S-8
Registration of securities for employees
7 Mar 24
6-K
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
7 Mar 24
20-F
2023 FY
Annual report (foreign)
7 Mar 24
6-K
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
26 Feb 24
6-K
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 23
6-K
Alpha Tau to Participate in Sidoti Small-Cap Conference
29 Nov 23
6-K
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
28 Nov 23
6-K
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
20 Nov 23
6-K
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
16 Nov 23
Latest ownership filings
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
18 Dec 23
144
Notice of proposed sale of securities
21 Nov 23
144
Notice of proposed sale of securities
9 Jun 23
144
Notice of proposed sale of securities
8 Jun 23
144
Notice of proposed sale of securities
8 Jun 23
144
Notice of proposed sale of securities
6 Jun 23
144
Notice of proposed sale of securities
2 Jun 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
1.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 4.08 bn |
Total shares | 948.57 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
C Citigroup | 337.76 k | $1.48 bn |
Corbin Capital Partners | 260.11 k | $1.14 bn |
Atalaya Capital Management | 73.74 k | $322.25 mm |
MS Morgan Stanley | 40.30 k | $176.12 mm |
JPM JPMorgan Chase & Co. | 39.18 k | $171.22 mm |
ProVise Management | 35.07 k | $153.26 mm |
Geode Capital Management | 33.08 k | $144.54 mm |
Grey Street Capital | 23.32 k | $101.92 mm |
Levin Capital Strategies | 20.00 k | $87.40 mm |
Circle Wealth Management | 14.50 k | $63.37 mm |